COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival | MicrobiomeTrials← Back to trialsNCT07729241
COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival
CompletedOBSERVATIONAL
Trial Details
Start: 2020-12-28Est. Completion: 2024-12-31
Enrollment target: 95,015 participants Locations- Hôpital Pitié Salpêtrière / CIC-2503, Paris, Paris, France
Other microbiome trials you might be interested in
Oesophageal Squamous Cell CarcinomaOesophageal AdenocarcinomaGastric AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)Colorectal Adenocarcinoma
The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlie…
Maidstone, United KingdomEst. completion Feb 2, 2028
Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Birmingham, United StatesEst. completion Nov 1, 2028
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to ass…
Duarte, United StatesEst. completion Jul 2027